항바이러스제 시장 : 적응증, 약제 클래스별, 투여 경로, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Antiviral Drugs Market is projected to grow by USD 100.83 billion at a CAGR of 6.99% by 2032.

The antiviral drugs market is evolving from episodic treatment toward continuous, surveillance-led disease management across HIV, hepatitis B, hepatitis C, influenza, herpesviruses, cytomegalovirus, respiratory syncytial virus, and SARS-CoV-2. Demand is supported by persistent viral disease burden, expanding immunocompromised populations, travel-related transmission, aging demographics, and public health preparedness programs that require rapid access to effective oral, injectable, and combination antivirals.

Verified public health data underscore the scale of need. The World Health Organization estimates that 39.9 million people were living with HIV in 2023, while chronic hepatitis B and hepatitis C affected approximately 254 million and 50 million people, respectively. WHO also reports that seasonal influenza causes around 1 billion infections annually, including 3 million to 5 million severe cases. These large treated and untreated populations keep antiviral drug discovery, generic access, long-acting formulations, pediatric options, and resistance monitoring at the center of pharmaceutical strategy.

Transformative Shifts in the Antiviral Landscape

The antiviral landscape is being reshaped by a shift from broad post-infection treatment to earlier, precision-based intervention. Direct-acting antivirals transformed hepatitis C care, integrase inhibitors and long-acting regimens are redefining HIV treatment, and oral COVID-19 antivirals reinforced the commercial and public health value of rapidly deployable therapies. Wider diagnostic availability, genomic surveillance, and treatment guidelines are also supporting faster therapy initiation and more targeted prescribing.

Market competition is moving beyond efficacy alone. Payers, health systems, and procurement agencies are prioritizing resistance profile, dosing convenience, drug-drug interaction management, real-world outcomes, tolerability, and manufacturing resilience. As patent expiries expand generic competition in mature categories, innovation is concentrating on novel mechanisms, pan-viral platforms, host-targeted antivirals, pediatric formulations, depot delivery, and therapies for underserved viral infections.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating antiviral drug discovery by improving target identification, structure-based design, lead optimization, and in silico screening against viral enzymes, entry proteins, and host factors. AI-enabled protein modeling and molecular simulation are reducing early research timelines, while machine learning helps prioritize compounds with favorable potency, safety, selectivity, and pharmacokinetic properties before costly laboratory validation.

AI is also strengthening clinical and commercial execution. Predictive analytics can identify patient cohorts at risk of severe infection, support adaptive trial design, monitor antiviral resistance, improve safety signal detection, and optimize pharmacovigilance from real-world evidence. The cumulative impact is a more responsive antiviral ecosystem that can move faster during outbreaks while improving lifecycle management for established therapies and supporting evidence-based market access.

Key Regional Insights for Antiviral Drugs

Asia-Pacific is a strategically important antiviral drugs region, driven by large patient populations, hepatitis prevalence, influenza seasonality, rising diagnostic coverage, and strong manufacturing capacity in China, India, Japan, South Korea, and Australia. China's biopharmaceutical policy support and India's established generic antiviral production are improving regional access, while Japan, South Korea, and Australia remain important markets for innovative therapies, national reimbursement pathways, and diagnostics-linked prescribing.

North America leads in antiviral innovation, clinical trial activity, regulatory execution, and rapid adoption of novel therapies, supported by U.S. FDA pathways, public health purchasing, advanced laboratory networks, and specialty pharmacy infrastructure. Europe benefits from centralized regulatory coordination, mature reimbursement systems, antimicrobial and antiviral stewardship programs, and sustained demand across HIV, hepatitis, influenza, and hospital-based viral infections. Latin America is expanding access through public procurement and generic adoption, with Brazil and Mexico acting as major demand centers for HIV, hepatitis, respiratory infection, and immunization-linked care pathways.

The Middle East is investing in healthcare modernization, outbreak preparedness, digital health infrastructure, and specialty care capacity, particularly across Gulf markets with centralized purchasing systems. Africa remains a critical access region due to high HIV and viral hepatitis burden, where donor-supported programs, national treatment guidelines, local distribution partnerships, and affordable generics are central to treatment continuity and equitable antiviral access.

Key Group Insights Across Major Economic Blocs

ASEAN markets are increasingly important for antiviral drug manufacturers because of dense populations, cross-border mobility, influenza and dengue surveillance needs, and expanding universal health coverage initiatives. Demand is strongest where public procurement can combine affordable generics with targeted access to innovative therapies for HIV, hepatitis, severe respiratory infections, and hospital-treated viral complications.

The GCC is characterized by high healthcare spending, centralized purchasing, medical infrastructure investment, and rapid uptake of premium hospital and specialty medicines, making it attractive for novel antivirals and preparedness stockpiles. The European Union provides a harmonized regulatory environment and substantial purchasing power, but market access success depends on health technology assessment outcomes, comparative effectiveness data, budget impact review, and pricing negotiations.

BRICS countries combine large disease burden with expanding domestic pharmaceutical capabilities, creating opportunities for technology transfer, local manufacturing, clinical research, and affordable treatment scale-up. G7 countries remain core centers for antiviral research, intellectual property generation, advanced clinical adoption, and regulatory science, while NATO member states increasingly view antivirals as part of health security, pandemic preparedness, military medical readiness, and supply chain resilience strategies.

Key Country Insights in Antiviral Drugs

The United States remains the largest innovation and commercialization hub for antiviral drugs, supported by FDA approvals, National Institutes of Health research funding, advanced diagnostics, clinical trial networks, and strong demand in HIV, COVID-19, influenza, hepatitis, and transplant-related viral infections. Canada emphasizes guideline-driven access, public reimbursement, and coordinated infectious disease care, while Mexico is expanding access through institutional purchasing, private-sector demand, and growing use of generic antiviral therapies.

Brazil leads Latin American antiviral demand through large public health programs, particularly in HIV and hepatitis, while local regulatory, tendering, and pricing dynamics shape market entry. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine high clinical standards with cost-effectiveness scrutiny; Germany and France are especially influential for evidence expectations, while the UK's National Health Service and NICE assessment processes shape value demonstration and reimbursement strategy.

Russia has domestic production priorities and demand across influenza, hepatitis, and HIV, though geopolitical and procurement factors affect international participation. In Asia-Pacific, China and India are pivotal due to scale, disease burden, and manufacturing capacity; Japan is a high-value market for innovative therapies and aging-population needs; Australia offers strong reimbursement pathways and surveillance-based public health policy; and South Korea combines advanced healthcare infrastructure, rapid diagnostics, and a growing biopharma sector.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated antiviral portfolios that address resistance, dosing burden, safety, drug-drug interactions, and unmet needs beyond crowded legacy categories. Investment should focus on long-acting HIV regimens, hepatitis B functional cure research, broad-spectrum respiratory antivirals, immunocompromised patient indications, pediatric formulations, and combination strategies that reduce viral escape.

Executives should also strengthen regional access models through tiered pricing, local manufacturing partnerships, public procurement engagement, regulatory readiness, and pharmacovigilance systems. Organizations that integrate AI-enabled discovery, real-world evidence generation, companion diagnostics, resistance surveillance, and resilient supply chains will be better positioned to compete in both routine care and outbreak-response environments.

Research Methodology

This executive summary is based on secondary research from verified public sources, including the World Health Organization, UNAIDS, national regulatory agencies, health technology assessment bodies, government procurement references, clinical guideline publications, peer-reviewed literature, and public health surveillance datasets. The analysis emphasizes validated epidemiology, regulatory trends, treatment guidelines, access policies, resistance considerations, and observable industry developments.

Insights are reviewed for consistency, relevance, and data integrity to support executive decision-making in the antiviral drugs market. The methodology excludes market sizing, market share, and forecasting, focusing instead on evidence-backed disease burden, therapeutic innovation, regional access dynamics, and strategic implications for antiviral drug development and commercialization.

Conclusion

The antiviral drugs market is entering a more strategic phase defined by precision medicine, rapid outbreak readiness, AI-supported discovery, resistance monitoring, and expanded access to proven therapies. Persistent global burdens from HIV, viral hepatitis, influenza, herpesviruses, RSV, cytomegalovirus, and SARS-CoV-2 ensure that antivirals remain essential to public health and pharmaceutical innovation.

Organizations that combine scientific differentiation with affordability, evidence generation, regulatory agility, and supply resilience will be best positioned to address evolving clinical and public health needs. The next wave of leadership will come from innovators capable of serving both high-value specialty markets and large-scale public health programs with reliable, data-driven antiviral solutions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antiviral Drugs Market, by Indication

• 7.1. Hepatitis B
• 7.2. Hepatitis C
• 7.3. Herpes Simplex
• 7.4. Hiv
• 7.5. Influenza
• 7.6. Respiratory Syncytial Virus

8. Antiviral Drugs Market, by Drug Class

• 8.1. Fusion Inhibitors
• 8.2. Integrase Inhibitors
• 8.3. Non Nucleoside Reverse Transcriptase Inhibitors
• 8.4. Nucleoside Analogues
• 8.5. Protease Inhibitors

9. Antiviral Drugs Market, by Route Of Administration

• 9.1. Inhalation
• 9.2. Injectable
• 9.3. Oral
• 9.4. Topical

10. Antiviral Drugs Market, by End User

• 10.1. Clinics
• 10.2. Home Care
• 10.3. Hospitals
• 10.4. Long Term Care Facilities

11. Antiviral Drugs Market, by Distribution Channel

• 11.1. Clinics
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Antiviral Drugs Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Antiviral Drugs Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Antiviral Drugs Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AbbVie Inc.
• 16.2. AstraZeneca plc
• 16.3. Aurobindo Pharma Limited
• 16.4. Bayer AG
• 16.5. Boehringer Ingelheim GmbH
• 16.6. Bristol-Myers Squibb Company
• 16.7. Cipla Limited
• 16.8. Dr. Reddy's Laboratories Ltd.
• 16.9. Gilead Sciences, Inc.
• 16.10. GlaxoSmithKline plc
• 16.11. Hetero Labs Limited
• 16.12. Johnson & Johnson Services Ltd.
• 16.13. Merck & Co., Inc.
• 16.14. Mylan N.V.
• 16.15. Novartis AG
• 16.16. Pfizer Inc.
• 16.17. Roche Holding AG
• 16.18. Sandoz International GmbH
• 16.19. Sanofi S.A.
• 16.20. Sun Pharmaceutical Industries Ltd.
• 16.21. Takeda Pharmaceutical Company Limited
• 16.22. Teva Pharmaceutical Industries Ltd.